Anna E Coghill1, Wei Bu2, Wan-Lun Hsu3,4, Hanh Nguyen2, Kelly J Yu1, Yin-Chu Chien4,5, Chien-Jen Chen3,4, Jeffrey I Cohen2, Allan Hildesheim1. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD. 2. Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD. 3. Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei. 4. Genomics Research Center, Academia Sinica, Taipei. 5. National Institute of Cancer Research, National Health Research Institute, Miaoli, Taiwan.
Abstract
Background: We previously reported that higher levels of antibody targeting Epstein-Barr virus (EBV) glycoprotein350 (gp350), an EBV vaccine candidate, were protective against nasopharyngeal carcinoma (NPC) in genetically high-risk families from Taiwan. The current study attempted to extend this association to a general population cohort. Methods: We compared total and IgA-specific gp350 antibody levels in 35 incident NPC cases and 81 disease-free controls from the Cancer Screening Program in Taiwan (23943 individuals recruited 1991-1992). Luciferase immunoprecipitation assays quantified gp350 antibody. Results: Total EBVgp350 antibody levels were not higher in individuals who remained disease free compared to those who developed NPC (P = .11). This lack of a protective gp350 association persisted for cases diagnosed ≥5 years (odds ratio [OR] = 1.05; P = .91) and <5 years (OR = 1.85; P = .40) after blood draw. IgA-specific gp350 antibody levels were higher in cases than controls (OR = 7.03; P = .001). This increased risk was most pronounced for cases diagnosed <5 years after blood draw (OR = 11.7; P = .004). Conclusion: Unlike our prior findings in those with a strong family history of NPC, total gp350 antibody levels were not protective against NPC development in this general population setting.
Background: We previously reported that higher levels of antibody targeting Epstein-Barr virus (EBV) glycoprotein350 (gp350), an EBV vaccine candidate, were protective against nasopharyngeal carcinoma (NPC) in genetically high-risk families from Taiwan. The current study attempted to extend this association to a general population cohort. Methods: We compared total and IgA-specific gp350 antibody levels in 35 incident NPC cases and 81 disease-free controls from the Cancer Screening Program in Taiwan (23943 individuals recruited 1991-1992). Luciferase immunoprecipitation assays quantified gp350 antibody. Results: Total EBVgp350 antibody levels were not higher in individuals who remained disease free compared to those who developed NPC (P = .11). This lack of a protective gp350 association persisted for cases diagnosed ≥5 years (odds ratio [OR] = 1.05; P = .91) and <5 years (OR = 1.85; P = .40) after blood draw. IgA-specific gp350 antibody levels were higher in cases than controls (OR = 7.03; P = .001). This increased risk was most pronounced for cases diagnosed <5 years after blood draw (OR = 11.7; P = .004). Conclusion: Unlike our prior findings in those with a strong family history of NPC, total gp350 antibody levels were not protective against NPC development in this general population setting.
Authors: W Henle; G Henle; H C Ho; P Burtin; Y Cachin; P Clifford; A de Schryver; G de-Thé; V Diehl; G Klein Journal: J Natl Cancer Inst Date: 1970-01 Impact factor: 13.506
Authors: Matti Lehtinen; Jorma Paavonen; Cosette M Wheeler; Unnop Jaisamrarn; Suzanne M Garland; Xavier Castellsagué; S Rachel Skinner; Dan Apter; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Henry Kitchener; Júlio C Teixeira; James Hedrick; Genara Limson; Anne Szarewski; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; Newton S De Carvalho; Maria Julieta V Germar; Klaus Peters; Adrian Mindel; Philippe De Sutter; F Xavier Bosch; Marie-Pierre David; Dominique Descamps; Frank Struyf; Gary Dubin Journal: Lancet Oncol Date: 2011-11-08 Impact factor: 41.316
Authors: Anna E Coghill; Wei Bu; Hanh Nguyen; Wan-Lun Hsu; Kelly J Yu; Pei-Jen Lou; Cheng-Ping Wang; Chien-Jen Chen; Allan Hildesheim; Jeffrey I Cohen Journal: Clin Cancer Res Date: 2016-02-26 Impact factor: 12.531
Authors: Karthik Sathiyamoorthy; Jiansen Jiang; Britta S Möhl; Jia Chen; Z Hong Zhou; Richard Longnecker; Theodore S Jardetzky Journal: Proc Natl Acad Sci U S A Date: 2017-09-22 Impact factor: 11.205